August 27, 2012
Kyowa Hakko Kirin’s Poteligeo (mogamulizumab) has gotten off to a good start as expected. Poteligeo is a humanized monoclonal antibody manufactured using the company’s proprietary POTELLIGENT technology, which enhances the activity of antibodies. It is indicated for the treatment of...read more